These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. Hutchinson M; Kappos L; Calabresi PA; Confavreux C; Giovannoni G; Galetta SL; Havrdova E; Lublin FD; Miller DH; O'Connor PW; Phillips JT; Polman CH; Radue EW; Rudick RA; Stuart WH; Wajgt A; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA; J Neurol; 2009 Mar; 256(3):405-15. PubMed ID: 19308305 [TBL] [Abstract][Full Text] [Related]
4. Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis. Zivadinov R; Dwyer MG; Hussein S; Carl E; Kennedy C; Andrews M; Hojnacki D; Heininen-Brown M; Willis L; Cherneva M; Bergsland N; Weinstock-Guttman B Mult Scler; 2012 Aug; 18(8):1125-34. PubMed ID: 22194217 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of natalizumab therapy in patients of African descent with relapsing multiple sclerosis: analysis of AFFIRM and SENTINEL data. Cree BA; Stuart WH; Tornatore CS; Jeffery DR; Pace AL; Cha CH Arch Neurol; 2011 Apr; 68(4):464-8. PubMed ID: 21482925 [TBL] [Abstract][Full Text] [Related]
6. MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. Fox RJ; Cree BA; De Sèze J; Gold R; Hartung HP; Jeffery D; Kappos L; Kaufman M; Montalbán X; Weinstock-Guttman B; Anderson B; Natarajan A; Ticho B; Duda P; Neurology; 2014 Apr; 82(17):1491-8. PubMed ID: 24682966 [TBL] [Abstract][Full Text] [Related]
7. Clinical effects of natalizumab on multiple sclerosis appear early in treatment course. Kappos L; O'Connor PW; Polman CH; Vermersch P; Wiendl H; Pace A; Zhang A; Hotermans C J Neurol; 2013 May; 260(5):1388-95. PubMed ID: 23292204 [TBL] [Abstract][Full Text] [Related]
8. Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a. Rudick RA; Pace A; Rani MR; Hyde R; Panzara M; Appachi S; Shrock J; Maurer SL; Calabresi PA; Confavreux C; Galetta SL; Lublin FD; Radue EW; Ransohoff RM Neurology; 2009 Jun; 72(23):1989-93. PubMed ID: 19506220 [TBL] [Abstract][Full Text] [Related]
9. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: analysis of MRI responses to treatment and correlation with Nab. Barbero P; Bergui M; Versino E; Ricci A; Zhong JJ; Ferrero B; Clerico M; Pipieri A; Verdun E; Giordano L; Durelli L; Mult Scler; 2006 Feb; 12(1):72-6. PubMed ID: 16459722 [TBL] [Abstract][Full Text] [Related]
10. Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS. Weinstock-Guttman B; Galetta SL; Giovannoni G; Havrdova E; Hutchinson M; Kappos L; O'Connor PW; Phillips JT; Polman C; Stuart WH; Lynn F; Hotermans C J Neurol; 2012 May; 259(5):898-905. PubMed ID: 22008873 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries. Putzki N; Yaldizli O; Mäurer M; Cursiefen S; Kuckert S; Klawe C; Maschke M; Tettenborn B; Limmroth V Eur J Neurol; 2010 Jan; 17(1):31-7. PubMed ID: 19614963 [TBL] [Abstract][Full Text] [Related]
12. An open-label safety and drug interaction study of natalizumab (Antegren) in combination with interferon-beta (Avonex) in patients with multiple sclerosis. Vollmer TL; Phillips JT; Goodman AD; Agius MA; Libonati MA; Giacchino JL; Grundy JS Mult Scler; 2004 Oct; 10(5):511-20. PubMed ID: 15471366 [TBL] [Abstract][Full Text] [Related]
14. Analysis of T2 intensity by magnetic resonance imaging of deep gray matter nuclei in multiple sclerosis patients: effect of immunomodulatory therapies. Pawate S; Wang L; Song Y; Sriram S J Neuroimaging; 2012 Apr; 22(2):137-44. PubMed ID: 21707826 [TBL] [Abstract][Full Text] [Related]
15. Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective study. Lanzillo R; Quarantelli M; Bonavita S; Ventrella G; Lus G; Vacca G; Prinster A; Orefice G; Tedeschi G; Brescia Morra V Acta Neurol Scand; 2012 Nov; 126(5):306-14. PubMed ID: 22107083 [TBL] [Abstract][Full Text] [Related]